Skip to content

2024 June 6 release
Compare
Choose a tag to compare
@brendanreardon brendanreardon released this 06 Jun 16:34
· 3 commits to main since this release
v.2024-06-06
029e1a6
This commit was created on GitHub.com and signed with GitHub’s verified signature.
GPG key ID: B5690EEEBB952194
Learn about vigilant mode.

Added entries:

  • (FDA) ALK fusions and sensitivity to alectinib for patients with non-small cell lung cancer.
  • (FDA) BRAF p.V600E/K (p.V600 variants), rearrangements, and fusions and sensitivity to tovorafenib for patients with low-grade glioma.
  • (FDA) EGFR p.L858R and exon 19 deletions and sensitivity to erlotinib for patients with non-small cell lung cancer.
  • (FDA) EGFR p.L858R and exon 19 deletions and sensitivity to gefitinib for patients with non-small cell lung cancer.

Revised entries:

  • (FDA) RET fusions and sensitivity to selpercatinib for patients with solid tumors is now indicated for pediatric patients aged 2 and older, in addition to adult patients.
  • (FDA) RET fusions and sensitivity to selpercatinib for patients with thyroid cancer is now indicated for pediatric patients aged 2 and older, revised from age 12 or older.
  • (FDA) RET variants and sensitivity to selpercatinib for patients with medullary thyroid cancer is now indicated for pediatric patients aged 2 and older, revised from age 12 or older.
  • (FDA) RET fusion and sensitivity to selpercatinib for patients with non-small cell lung cancer's description and publication date were revised.
Assets 2
Loading